We assessed T22‐GFP‐H6‐FdU capacity to inhibit growth of established metastases, as compared to equimolecular doses of T22‐GFP‐H6 or free oligo‐FdU, using an orthotopic bioluminescent CXCR4+ CRC model in Swiss nude mice, which generates lymph node (LN) and lung (LG) metastases (Mets), starting therapy 2 months after CRC cell implantation, given a 20 μg i.v. q3d dosage (Appendix Fig S5A). The gene discussed is CXCR4; the disease is colorectal carcinoma.